BALTIMORE, July 14, 2015 /PRNewswire/ -- Ingenuity Health, a service of Ameritox, Ltd., a leading provider of medication monitoring solutions to behavioral health clinicians, today expanded its comprehensive reference database that helps clinicians assess medication adherence among patients with Serious Mental Illness. Ingenuity Health has developed a method to help assess adherence in patients prescribed the antipsychotic drug lurasidone, marketed under the brand name Latuda®. The reference database provides behavioral health clinicians help in addressing the ongoing problem of medication non-adherence in those with SMI.
Ingenuity Health conducted clinical research to provide additional information about whether a patient may be taking lurasidone as prescribed. By comparing normalized urine drug results against the results of a reference database of patients clinically assessed as adherent, Ingenuity Health's results will provide behavioral health centers and medical professionals more information as they manage and treat patients prescribed lurasidone.
"Because medication adherence remains a challenge among those with behavioral health conditions, the more medications for which we can provide additional insight, the better clinicians can help their patients," said Jerry Vaccaro, M.D., President of Ingenuity Health.
Lurasidone is the fourth antipsychotic medication for which Ingenuity Health has established a reference range for better assessing medication adherence. Ingenuity Health previously introduced reference ranges for quetiapine extended release (Seroquel XR®), risperidone (Risperdal®), and aripiprazole (Abilify®), one of the top-selling medications in the U.S.
The reference database leverages the technology of Ameritox's exclusive Rx Guardian CDSM, which goes beyond traditional data gathering to provide analysis that can help clinicians address the growing problem of pain medication misuse, abuse and diversion.
Ameritox previously established proprietary reference ranges for commonly prescribed opioids, including hydrocodone, oxycodone, oxymorphone, morphine and methadone.
About Ingenuity Health
As a service of AmeritoxSM, a national leader in medication monitoring solutions, Ingenuity Health utilizes urine drug monitoring to provide highly reliable data and analysis that help doctors and behavioral health specialists improve treatment for patients diagnosed with serious mental illness (SMI).
Visit the Ingenuity Health website at: www.ingenuityhealth.com
Follow Ingenuity Health on Twitter: www.twitter.com/ingenuityhealth
Ameritox's prescription drug monitoring services help address the national epidemic of prescription drug misuse, abuse, and diversion. As a national leader in medication monitoring solutions, Ameritox provides medical and business professionals with health care solutions that can help improve patient care and prevent tragedy. Ameritox, headquartered in Baltimore, Md., has 800 employees nationwide and laboratory facilities in Greensboro, N.C.
Visit the Ameritox website at: www.ameritox.com
Follow Ameritox on Twitter: www.twitter.com/ameritox
Director of Communications, Ameritox
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ingenuity-health-expands-reference-database-to-help-assess-medication-adherence-in-those-with-serious-mental-illness-300112507.html
SOURCE Ingenuity Health